Legend Biotech (LEGN) Receivables (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Receivables data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Receivables rose 28.5% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 28.5% YoY) and the FY2025 annual result came in at $13.1 million, up 82.45% from the prior year.
• Receivables eased to $1.7 million in Q1 2026, from $13.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $100.8 million in Q4 2023 to a low of $56000.0 in Q1 2023.
• A 5-year average of $22.6 million and a median of $7.2 million in 2024 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 9613.97% in 2023, down 99.89% in 2023.
• Tracing LEGN's Receivables over 5 years: stood at $1.0 million in 2022, then jumped by 9613.97% to $100.8 million in 2023, then slumped by 92.88% to $7.2 million in 2024, then jumped by 82.45% to $13.1 million in 2025, then slumped by 87.02% to $1.7 million in 2026.
• The last three Receivables figures came in at $1.7 million (Q1 2026), $13.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.